GlaxoSmithKline makes $300M investment in 23andMe, forms 50-50 R&D pact
Make no mistake about what is happening here. GSK is buying access to all of the genetic data that 23andMe has. This is why I am wary to use any 23andMe type of service.<p>&quot;The partners plan to use 23andMe’s data to jointly discover drug targets.&quot;<p>They will claim all kinds of protections of course, but it is only a matter of time until genetic data starts being resold.